Processa Pharmaceuticals (PCSA) Operating Income (2012 - 2026)

Processa Pharmaceuticals (PCSA) has reported Operating Income for 15 consecutive years, with -$2.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Income rose 40.87% year-over-year to -$2.3 million; the trailing twelve-month figure through Jun 2026 stood at -$12.9 million (up 0.77% YoY), and the FY2025 full-year result was -$14.0 million, down 16.08% from the prior year.
• Operating Income grew to -$2.3 million in Q2 2026 per PCSA's latest filing, from -$3.3 million in the prior quarter.
• Across five years, Operating Income topped out at -$2.2 million in Q3 2023 and bottomed at -$13.1 million in Q4 2022.
• Historically, Operating Income has averaged -$3.9 million across 5 years, with a median of -$3.3 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Operating Income slumped 287.88% in 2022, then soared 81.1% in 2023.
• Over 5 years, Operating Income stood at -$13.1 million in 2022, then jumped by 81.1% to -$2.5 million in 2023, then decreased by 10.74% to -$2.7 million in 2024, then slumped by 35.37% to -$3.7 million in 2025, then surged by 36.89% to -$2.3 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered -$2.3 million, -$3.3 million, and -$3.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.